Amarin Corp Plc (AMRN)

[Jeffkad]

JL, a question. I am one of those that has labeled AMRN a one drug wonder, and yet I fully understand the potential of Vascepa. My distinction is that AMRN has no pipeline of different drugs, only a potential pipeline of different indications for the same drug, which has a patent expiry in 10 years. Perhaps I don’t understand patent applicability, so answer me this: if AMRN runs new trials and finds new applications that receive FDA approval, can they extend the patent protection for these new indications even as it expires for the current/hopeful trig lowering/CVD indication? Or is the 2029 patent expiration etched in stone for the process of creating IE regardless? If it’s the former, I stand corrected. If it’s the latter, then I stand by my one hit wonder assertion, since the amount of time needed to complete new trials and get FDA approval would leave little time left on the patent-protected runway.